In patients who do not respond adequately to maximally tolerated colchicine therapy or who develop complications such as amyloidosis, treatment is escalated to IL-1 inhibitors (such as anakinra or canakinumab), IL-6, TNF-α, and biologic agents targeting the JAK pathways, in accordance with national and international guidelines. The gene discussed is IL1B; the disease is amyloidosis.